- Home
- VRDN vs ANIP Comparison
VRDN vs ANIP Comparison
Compare VRDN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- ANIP
- Stock Information
- Founded
- VRDN 2006
- ANIP 2001
- Country
- VRDN United States
- ANIP United States
- Employees
- VRDN N/A
- ANIP N/A
- Industry
- VRDN Medical Specialities
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- ANIP Health Care
- Exchange
- VRDN Nasdaq
- ANIP Nasdaq
- Market Cap
- VRDN 1.3B
- ANIP 1.4B
- IPO Year
- VRDN N/A
- ANIP N/A
- Fundamental
- Price
- VRDN $17.28
- ANIP $67.48
- Analyst Decision
- VRDN Strong Buy
- ANIP Strong Buy
- Analyst Count
- VRDN 11
- ANIP 9
- Target Price
- VRDN $38.50
- ANIP $80.56
- AVG Volume (30 Days)
- VRDN 667.1K
- ANIP 288.7K
- Earning Date
- VRDN 08-07-2025
- ANIP 08-05-2025
- Dividend Yield
- VRDN N/A
- ANIP N/A
- EPS Growth
- VRDN N/A
- ANIP N/A
- EPS
- VRDN N/A
- ANIP N/A
- Revenue
- VRDN $302,000.00
- ANIP $674,068,000.00
- Revenue This Year
- VRDN N/A
- ANIP $30.84
- Revenue Next Year
- VRDN $17,102.33
- ANIP $7.39
- P/E Ratio
- VRDN N/A
- ANIP N/A
- Revenue Growth
- VRDN 4.86
- ANIP 30.27
- 52 Week Low
- VRDN $9.90
- ANIP $52.50
- 52 Week High
- VRDN $27.20
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- VRDN 60.64
- ANIP 58.60
- Support Level
- VRDN $16.46
- ANIP $64.27
- Resistance Level
- VRDN $18.44
- ANIP $68.20
- Average True Range (ATR)
- VRDN 0.81
- ANIP 2.04
- MACD
- VRDN 0.04
- ANIP 0.09
- Stochastic Oscillator
- VRDN 57.82
- ANIP 77.60
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.